Ataxic Symptoms in Huntington's Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone

被引:14
|
作者
Egorova, Polina A. [1 ]
Gavrilova, Aleksandra V. [1 ]
Bezprozvanny, Ilya B. [1 ,2 ]
机构
[1] Peter Great St Petersburg Polytech Univ, Lab Mol Neurodegenerat, St Petersburg, Russia
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, Dallas, TX USA
基金
俄罗斯科学基金会;
关键词
ataxia; cerebellum; Huntington's disease; transgenic mice; chlorzoxazone; BETA-III SPECTRIN; PURKINJE-CELLS; POTASSIUM CHANNELS; CEREBELLAR-ATAXIA; TRINUCLEOTIDE REPEAT; DOUBLE-BLIND; DYSFUNCTION; MOTOR; GENE; MODULATOR;
D O I
10.3389/fnins.2020.00279
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a hereditary neurodegenerative disease caused by a polyglutamine expansion in the huntingtin protein, Striatum atrophy in HD leads to a progressive disturbance of psychiatric, motor, and cognitive function. Recent studies of HD patients revealed that the degeneration of cerebellum is also observed independently from the striatal atrophy during early HD stage and may contribute to the motor impairment and ataxia observed in HD. Cerebellar Purkinje cells (PCs) are responsible for the proper cerebellar pathways functioning and motor control. Recent studies on mouse models of HD have shown that the abnormality of the biochemical functions of PCs are observed in HD, suggesting the contribution of PC dysfunction and death to the impaired movement coordination observed in HD. To investigate ataxic symptoms in HD we performed a series of experiments with the yeast artificial chromosome transgenic mouse model of HD (YAC128). Using extracellular single-unit recording method we found that the portion of the cerebellar PCs with bursting and irregular patterns of spontaneous activity drastically rises in aged YAC128 HD mice when compared with wild type littermates. Previous studies demonstrated that SK channels are responsible for the cerebellar PC pacemaker activity and that positive modulation of SK channel activity exerted beneficial effects in different ataxic mouse models. Here we studied effects of the SK channels modulator chlorzoxazone (CHZ) on the motor behavior of YAC128 HD mice and also on the electrophysiological activity and neuroanatomy of the cerebellar PCs from these mice. We determined that the long-term intraperitoneal injections of CHZ alleviated the progressive impairment in the firing pattern of YAC128 PCs. We also demonstrated that treatment with CHZ rescued age-dependent motor incoordination and improved the cerebellar morphology in YAC128 mice. We propose that abnormal changes in the PC firing patterns might be a one of the possible causes of ataxic symptoms in HD and in other polyglutamine disorders and that the pharmacological activation of SK channels may serve as a potential way to improve the activity of cerebellar PCs and relieve the ataxic phenotype in HD patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Neuroprotective effects of kynurenic acid analog in a transgenic mouse model of Huntington's disease
    Klivenyi, P.
    Zadori, D.
    Fulop, F.
    Toldi, J.
    Vecsei, L.
    MOVEMENT DISORDERS, 2009, 24 : S166 - S166
  • [32] Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington's Disease
    Wood, Nigel I.
    Sawiak, Stephen J.
    Buonincontri, Guido
    Niu, Youguo
    Kane, Andrew D.
    Carpenter, T. Adrian
    Giussani, Dino A.
    Morton, A. Jennifer
    JOURNAL OF HUNTINGTONS DISEASE, 2012, 1 (01) : 57 - 64
  • [33] Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington's disease
    Kong, Geraldine
    Kim-Anh Le Cao
    Judd, Louise M.
    Li, ShanShan
    Renoir, Thibault
    Hannan, Anthony J.
    NEUROBIOLOGY OF DISEASE, 2020, 135
  • [34] Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease
    Cuesta, Marc
    Aungier, Juliet
    Morton, A. Jennifer
    NEUROBIOLOGY OF DISEASE, 2014, 63 : 85 - 91
  • [35] EVALUATION OF PRIDOPIDINE IN THE TRANSGENIC YAC128 MOUSE MODEL OF HUNTINGTON'S DISEASE
    Miralles, Marta Garcia
    Tan, Liang Juin
    Lim, Madeline
    Geva, Michal
    Hayden, Michael R.
    Pouladi, Mahmoud A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A92 - A92
  • [36] Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease
    Zadori, Denes
    Geisz, Andrea
    Vamos, Eniko
    Vecsei, Laszlo
    Klivenyi, Peter
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 94 (01) : 148 - 153
  • [37] Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model
    Mohammed, Abuelnor
    Ramadan, Azza
    Elnour, Asim Ahmed
    Saeed, Ali Awadallah Ali Mohamed
    Al Mazrouei, Nadia
    Alsulami, Fahad T.
    Alqarni, Yousef Saeed
    Menon, Vineetha
    Al Amoodi, Abdulla
    Abdalla, Sami Fatehi
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (09)
  • [38] Experimental therapeutics in transgenic mouse models of Huntington's disease
    Beal, MF
    Ferrante, RJ
    NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 373 - 384
  • [39] Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse
    Higgins, DS
    Hoyt, KR
    Baic, C
    Vensel, J
    Sulka, M
    OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS, 1999, 893 : 298 - 300
  • [40] Experimental therapeutics in transgenic mouse models of Huntington's disease
    M. Flint Beal
    Robert J. Ferrante
    Nature Reviews Neuroscience, 2004, 5 : 373 - 384